Gene therapy upstarts NightStaRx and Genenta raise venture cash; Syndax pulls an IPO;

@FierceBiotech: Sanofi, Regeneron capture a shot at first-mover advantage in the PCSK9 market. Report | Follow @FierceBiotech

@JohnCFierce: Rockwell's dialysis drug wins an FDA OK, despite lingering doubts. Article | Follow @JohnCFierce

@DamianFierce: Under-rated aspect of $GILD's hep C dominance: correctly spelling "hepatology." More | Follow @DamianFierce

> London-based NightStaRx has banked new venture cash and recruited J&J ($JNJ) veteran David Fellows as its new CEO. The company is developing new gene therapies, with a lead program for Choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Release

> The Milan-based gene therapy biotech Genenta has raised 6 million euros for its R&D work. Story

> Syndax has pulled its $60 million IPO. Story

Medical Device News

@FierceMedDev: ICYMI: Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. Report | Follow @FierceMedDev

@VarunSaxena2: GE Healthcare says strong U.S. growth offset weakness abroad. Story | Follow @VarunSaxena2

@EmilyWFierce: Obama and Narendra Modi scheduled to meet with top U.S. and Indian execs today to discuss business barriers. Story from the WSJ (sub. req.) | Follow @EmilyWFierce

> Study shows ventricular assist devices allow diseased hearts to regenerate muscle. Story

> Neurostim dry eye startup backed by Kleiner Perkins, NEA readies for CE mark. More

> FDA approves first glucose-monitoring app for mobile devices. Article

Pharma News

@FiercePharma: Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Actavis explains the recall of generic Neurontin was limited to 2,000 bottles shipped to one customer. FiercePharmaManufacturing story | Follow @EricPFierce

> Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales. More

> Gilead discounts hep C meds in Germany, offers new-and-improved generics deal in India. News

Biotech IT News

> EMA posts guide to help IT teams with its new pharmacovigilance database. News

> Obama talks up precision meds, cybersecurity in SOTU speech. More

> $4B VC shop lays out its vision for the future of digital health. Story

> GoBalto eyes Asian expansion after $12M Mitsui-led financing. Report

> BIO is preparing small biotechs for life in the social media maelstrom. Article

CRO News

> Trial tech outfit goBalto bags $12M to expand around the world. Report

> PPD beefs up its Irish outpost with a new biologics lab. News

> Australian CRO Novotech firms up its Hong Kong presence. More

> EMA wants more than 700 drugs suspended over GVK data scandal. Story

> Covance pools its early-stage R&D services into one offering. Article

Animal Health News

> Report: Merck said to be testing lower dosage Zilmax to revive sales. More

> Bayer study reveals growth opportunity for vet clinics in fighting parasites. Item

> Valeant CEO quashes rumors of Zoetis buyout bid. Article

> Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. Story

> Report: Livestock research lab prioritizes profits over animal health. More

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.